Exhaled nitric oxide in pulmonary diseases a comprehensive review

Chest

Volumn 138, Issue 3, 2010, Pages 682-692

  Barnes, Peter J ^a   Dweik, Raed A ^c   Gelb, Arthur F ^d,e   Gibson, Peter G ^g   George, Steven C ^f   Grasemann, Hartmut ^h   Pavord, Ian D ^b   Ratjen, Felix ^h   Silkoff, Philip E ^j   Taylor, D Robin ^k   Zamel, Noe ⁱ  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Lakewood Regional Medical Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g JOHN HUNTER HOSPITAL   (Australia)

^h HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF OTAGO   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LEUKOTRIENE RECEPTOR AFFECTING AGENT; LONG ACTING DRUG; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PREDNISONE; STEROID; THEOPHYLLINE;

AIRWAY; ALGORITHM; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE CONTROL; EOSINOPHIL; EOSINOPHILIC AIRWAY INFLAMMATION; EXHALATION; EXPIRATORY FLOW RATE; HUMAN; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG EMPHYSEMA; LUNG VASCULAR RESISTANCE; OXIDATIVE STRESS; PATHOGENESIS; PATIENT MONITORING; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SMOKING; SPIROMETRY; STEROID THERAPY; UPREGULATION; VASCULAR ENDOTHELIUM; BREATH ANALYSIS; HYPERTENSION, PULMONARY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ASTHMA; BREATH TESTS; EXHALATION; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77956791391     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-2090     Document Type: Review

References (110)

1. Lim KG, Mottram C. The use of fraction of exhaled nitric oxide in pulmonary practice. Chest. 2008;133(5):1232-1242. (Pubitemid 351685531)
2. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol Rev. 2004;84(3):731-765.
3. Donnelly LE, Barnes PJ. Expression and regulation of inducible nitric oxide synthase from human primary airway epithelial cells. Am J Respir Cell Mol Biol. 2002;26(1):144-151.
4. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol. 2002;64:749-774.
5. Bernareggi M, Mitchell JA, Barnes PJ, Belvisi MG. Dual action of nitric oxide on airway plasma leakage. Am J Respir Crit Care Med. 1997;155(3):869-874. (Pubitemid 27133396)
6. Ravi K, Brennan LA, Levic S, Ross PA, Black SM. S-nitrosylation of endothelial nitric oxide synthase is associated with monomerization and decreased enzyme activity. Proc Natl Acad Sci U S A. 2004;101(8):2619-2624.
7. Brindicci C, Kharitonov S, Ito M, et al. Nitric oxide synthase isoenzyme expression and activity in peripheral lung tissue of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:21-30.
8. Ward JK, Belvisi MG, Fox AJ, et al. Modulation of cholinergic neural bronchoconstriction by endogenous nitric oxide and vasoactive intestinal peptide in human airways in vitro. J Clin Invest. 1993;92(2):736-742.
9. Maarsingh H, Leusink J, Bos IS, Zaagsma J, Meurs H. Arginase strongly impairs neuronal nitric oxide-mediated airway smooth muscle relaxation in allergic asthma. Respir Res. 2006;7:6.
10. Jang AS, Choi IS, Lee JU. Neuronal nitric oxide synthase is associated with airway obstruction in BALB/c mice exposed to ozone. Respiration. 2003;70(1):95-99.
11. Brindicci C, Ito K, Barnes PJ, Kharitonov SA. Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity. Chest. 2007;131(5):1353-1362.
12. Brindicci C, Ito K, Resta O, Pride NB, Barnes PJ, Kharitonov SA. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J. 2005;26(1):52-59.
13. Saleh D, Ernst P, Lim S, Barnes PJ, Giaid A. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. FASEB J. 1998;12(11):929-937.
14. Ricciardolo FL, Caramori G, Ito K, et al. Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2005;116(5):1028-1035.
15. Osoata GO, Hanazawa T, Brindicci C, et al. Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest. 2009;135(6):1513-1520.
16. Brindicci C, Ito K, Barnes PJ, Kharitonov SA. Effect of an inducible nitric oxide synthase inhibitor on differential flow-exhaled nitric oxide in asthmatic patients and healthy volunteers. Chest. 2007;132(2):581-588. (Pubitemid 47282392)
17. Hansel TT, Kharitonov SA, Donnelly LE, et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J. 2003;17(10):1298-1300.
18. Singh D, Richards D, Knowles RG, et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med. 2007;176(10): 988-993.
19. Gustafsson LE, Leone AM, Persson MG, Wiklund NP, Moncada S. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun. 1991;181(2):852-857.
20. Silkoff PE, McClean PA, Slutsky AS, et al. Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am J Respir Crit Care Med. 1997;155(1):260-267.
21. 2. J Clin Invest. 1974;54(1):54-68.
22. Tsoukias NM, Tannous Z, Wilson AF, George SC. Single-exhalation profiles of NO and CO2 in humans: effect of dynamically changing flow rate. J Appl Physiol. 1998;85(2):642-652.
23. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol. 1998; 85(2):653-666.
24. Högman M, Drca N, Ehrstedt C, Meriläinen P. Exhaled nitric oxide partitioned into alveolar, lower airways and nasal contributions. Respir Med. 2000;94(10):985-991.
25. Jörres RA. Modelling the production of nitric oxide within the human airways. Eur Respir J. 2000;16(3):555-560.
26. Pietropaoli AP, Perillo IB, Torres A, et al. Simultaneous measurement of nitric oxide production by conducting and alveolar airways of humans. J Appl Physiol. 1999;87(4):1532-1542. (Pubitemid 29483144)
27. Silkoff PE, Sylvester JT, Zamel N, Permutt S. Airway nitric oxide diffusion in asthma: Role in pulmonary function and bronchial responsiveness. Am J Respir Crit Care Med. 2000; 161(4 Pt 1):1218-1228.
28. George SC, Hogman M, Permutt S, Silkoff PE. Modeling pulmonary nitric oxide exchange. J Appl Physiol. 2004;96(3):831-839. (Pubitemid 38248651)
29. Shin HW, Condorelli P, George SC. Examining axial diffusion of nitric oxide in the lungs using heliox and breath hold. J Appl Physiol. 2006;100(2):623-630.
30. Shin HW, Condorelli P, Rose-Gottron CM, Cooper DM, George SC. Probing the impact of axial diffusion on nitric oxide exchange dynamics with heliox. J Appl Physiol. 2004;97(3):874-882.
31. Shin HW, George SC. Impact of axial diffusion on nitric oxide exchange in the lungs. J Appl Physiol. 2002;93(6):2070-2080.
32. Van Muylem A, Noël C, Paiva M. Modeling of impact of gas molecular diffusion on nitric oxide expired profile. J Appl Physiol. 2003;94(1):119-127.
33. Condorelli P, Shin HW, Aledia AS, Silkoff PE, George SC. A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. J Appl Physiol. 2007;102(1):417-425.
34. Kerckx Y, Michils A, Van Muylem A. Airway contribution to alveolar nitric oxide in healthy subjects and stable asthma patients. J Appl Physiol. 2008;104(4):918-924. (Pubitemid 351507926)
35. Mahut B, Delacourt C, Zerah-Lancner F, De Blic J, Harf A, Delclaux C. Increase in alveolar nitric oxide in the presence of symptoms in childhood asthma. Chest. 2004;125(3):1012-1018.
36. Paraskakis E, Brindicci C, Fleming L, et al. Measurement of bronchial and alveolar nitric oxide production in normal children and children with asthma. Am J Respir Crit Care Med. 2006;174(3):260-267.
37. Gelb AF, Flynn Taylor C, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest. 2006;129(6): 1492-1499.
38. Gelb AF, Taylor CF, Nussbaum E, et al. Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med. 2004;170(7):737-741.
39. Lehtimäki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma. Eur Respir J. 2001;18(4):635-639. (Pubitemid 33040621)
40. Shin HW, Rose-Gottron CM, Cooper DM, Newcomb RL, George SC. Airway diffusing capacity of nitric oxide and steroid therapy in asthma. J Appl Physiol. 2004;96(1):65-75.
41. Suresh V, Shelley DA, Shin HW, George SC. Effect of heterogeneous ventilation and nitric oxide production on exhaled nitric oxide profiles. J Appl Physiol. 2008;104(6):1743-1752.
42. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912-930.
43. Taylor DR, Pavord ID. Biomarkers in the assessment and management of airways diseases. Postgrad Med J. 2008;84(998):628-634.
44. Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy. 2005;35(9): 1175-1179.
45. Brown HM. Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. Lancet. 1958;2(7059):1245-1247.
46. Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax. 2005;60(3):215-218.
47. Zacharasiewicz A, Wilson N, Lex C, et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med. 2005;171(10):1077-1082.
48. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med. 2005;172(4):453-459.
49. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med. 2007;176(3): 231-237.
50. Bacci E, Cianchetti S, Bartoli M, et al. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest. 2006;129(3):565-572.
51. Brightling CE, Symon FA, Birring SS, Bradding P, Wardlaw AJ, Pavord ID. Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax. 2003;58(6):528-532.
52. Corradi M, Majori M, Cacciani GC, Consigli GF, de'Munari E, Pesci A. Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease. Thorax. 1999; 54(7):572-575.
53. Hewitt RS, Smith AD, Cowan JO, Schofield JC, Herbison GP, Taylor DR. Serial exhaled nitric oxide measurements in the assessment of laboratory animal allergy. J Asthma. 2008;45(2):101-107.
54. Olivieri M, Talamini G, Corradi M, et al. Reference values for exhaled nitric oxide (reveno) study. Respir Res. 2006;7:94.
55. Olin AC, Rosengren A, Thelle DS, Lissner L, Bake B, Torén K. Height, age, and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample. Chest. 2006;130(5):1319-1325.
56. Olin AC, Bake B, Torén K. Fraction of exhaled nitric oxide at 50 mL/s: reference values for adult lifelong never-smokers. Chest. 2007;131(6):1852-1856. (Pubitemid 46981645)
57. Travers J, Marsh S, Aldington S, et al. Reference ranges for exhaled nitric oxide derived from a random community survey of adults. Am J Respir Crit Care Med. 2007;176(3):238-242.
58. Dressel H, de la Motte D, Reichert J, et al. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir Med. 2008;102(7): 962-969.
59. Smith AD, Cowan JO, Taylor DR. Exhaled nitric oxide levels in asthma: Personal best versus reference values. J Allergy Clin Immunol. 2009;124(4):714-718., e4.
60. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med. 2005;172(7):831-836.
61. Massaro AF, Gaston B, Kita D, Fanta C, Stamler JS, Drazen JM. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med. 1995;152(2):800-803.
62. Jones SL, Herbison P, Cowan JO, et al. Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship. Eur Respir J. 2002;20(3):601-608.
63. Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, Zamel N. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest. 2001;119(5):1322-1328.
64. Ghiro L, Zanconato S, Rampon O, Piovan V, Pasquale MF, Baraldi E. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J. 2002;20(3):630-634.
65. de Jongste JC, Carraro S, Hop WC, Baraldi E; CHARISM Study Group. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med. 2009;179(2):93-97.
66. Pijnenburg MW, Bakker EM, Lever S, Hop WC, De Jongste JC. High fractional concentration of nitric oxide in exhaled air despite steroid treatment in asthmatic children. Clin Exp Allergy. 2005;35(7):920-925.
67. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352(21):2163-2173.
68. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet. 2008;372(9643): 1065-1072.
69. Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies. Clin Exp Allergy. 2009;39(4):478-490.
70. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218-224.
71. Michils A, Baldassarre S, Van Muylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J. 2008;31(3):539-546.
72. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715-1721.
73. Jones SL, Kittelson J, Cowan JO, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med. 2001;164(5):738-743.
74. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001;323(7307):253-256.
75. Heresi GA, Dweik RA. Pulmonary hypertension: evaluation and management. Compr Ther. 2007;33(3):150-161.
76. Ghamra ZW, Dweik RA. Primary pulmonary hypertension: an overview of epidemiology and pathogenesis. Cleve Clin J Med. 2003;70(Suppl 1):S2-S8.
77. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation. 2000;102(22):2781-2791.
78. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84(24):9265-9269.
79. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327(6122):524-526. (Pubitemid 17085822)
80. Dweik RA, Laskowski D, Abu-Soud HM, et al. Nitric oxide synthesis in the lung. Regulation by oxygen through a kinetic mechanism. J Clin Invest. 1998;101(3):660-666.
81. Dweik RA. Pulmonary hypertension and the search for the selective pulmonary vasodilator. Lancet. 2002;360(9337): 886-887. (Pubitemid 35472168)
82. Kaneko FT, Arroliga AC, Dweik RA, et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med. 1998;158(3):917-923.
83. Dweik RA. The lung in the balance: arginine, methylated arginines, and nitric oxide. Am J Physiol Lung Cell Mol Physiol. 2007;292(1):L15-L17.
84. Ozkan M, Dweik RA, Laskowski D, Arroliga AC, Erzurum SC. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung. 2001;179(4):233-243.
85. Girgis RE, Frost AE, Hill NS, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis. 2007;66(11):1467-1472.
86. Machado RF, Londhe Nerkar MV, Dweik RA, et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. Free Radic Biol Med. 2004;37(7):1010-1017.
87. de Winter-de Groot KM, van der Ent CK. Nitric oxide in cystic fibrosis. J Cyst Fibros. 2005;4(Suppl 2):25-29.
88. Hubert D, Aubourg F, Fauroux B, et al. Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments. Eur Respir J. 2009;34(1):117-124.
89. Keen C, Olin AC, Edentoft A, Gronowitz E, Strandvik B. Airway nitric oxide in patients with cystic fibrosis is associated with pancreatic function, Pseudomonas infection, and polyunsaturated fatty acids. Chest. 2007;131(6): 1857-1864.
90. Moeller A, Horak F Jr, Lane C, et al. Inducible NO synthase expression is low in airway epithelium from young children with cystic fibrosis. Thorax. 2006;61(6):514-520.
91. Grasemann H, Knauer N, Büscher R, Hübner K, Drazen JM, Ratjen F. Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am J Respir Crit Care Med. 2000;162(6):2172-2176.
92. Grasemann H, Schwiertz R, Matthiesen S, Racké K, Ratjen F. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med. 2005;172(12):1523-1528. (Pubitemid 43076540)
93. Grasemann H, Schwiertz R, Grasemann C, Vester U, Racké K, Ratjen F. Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis. Respir Res. 2006;7:87.
94. Grasemann H, Kurtz F, Ratjen F. Inhaled l -arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med. 2006;174(2):208-212.
95. Ho LP, Innes JA, Greening AP. Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis. Eur Respir J. 1998;12(6):1290-1294.
96. Gaston B, Ratjen F, Vaughan JW, et al. Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal therapy. Am J Respir Crit Care Med. 2002;165(3):387-390.
97. Wooldridge JL, Deutsch GH, Sontag MK, et al. NO pathway in CF and non-CF children. Pediatr Pulmonol. 2004;37(4):338-350.
98. Hofer M, Mueller L, Rechsteiner T, Benden C, Boehler A. Extended nitric oxide measurements in exhaled air of cystic fibrosis and healthy adults. Lung. 2009;187(5):307-313.
99. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulminary disease. Am J Respir Crit Care Med. 2006;174(1):6-14.
100. Ansarin K, Chatkin JM, Ferreira IM, Gutierrez CA, Zamel N, Chapman KR. Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function. Eur Respir J. 2001;17(5):934-938.
101. Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(3 Pt 1): 998-1002.
102. Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(5):1773-1777.
103. Kunisaki KM, Rice KL, Janoff EN, Rector TS, Niewoehner DE. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. Ther Adv Respir Dis. 2008;2(2):55-64.
104. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906-913.
105. Berry M, Hargadon B, Morgan A, et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J. 2005;25(6):986-991.
106. van Veen IH, Sterk PJ, Schot R, Gauw SA, Rabe KF, Bel EH. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J. 2006;27(5): 951-956.
107. Högman M, Holmkvist T, Wegener T, et al. Extended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis. Respir Med. 2002;96(1):24-30.
108. Gelb AF, Taylor CF, Krishnan A, et al. Central and peripheral airway sites of nitric oxide gas exchange in COPD. Chest. 2010;137(3):575-584.
109. Roy K, Borrill ZL, Starkey C, et al. Use of different exhaled nitric oxide multiple flow rate models in COPD. Eur Respir J. 2007;29(4):651-659.
110. Dummer JF, Epton MJ, Cowan JO, et al. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med. 2009;180(9):846-852.